FDA Transparency Initiative: Disclosure Rules Could Expand, Then Be Harmonized
Executive Summary
Following the release of FDA's Transparency Task Force report, the agency may want to add an agenda item to its harmonization discussions with EMA
You may also be interested in...
FDA Pushes Back Against “Living” Benefit-Risk Assessment Management Plan
The Institute of Medicine urges the agency to create a publicly available document setting forth benefits and risks of drugs, with periodic updates, but FDA says it has no extra resources to handle such an effort.